Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Biology (Basel) ; 12(11)2023 Nov 02.
Article in English | MEDLINE | ID: mdl-37997994

ABSTRACT

Intense changes in mineral and bone metabolism are frequent in chronic kidney disease (CKD) and represent an important cause of morbidity and reduced quality of life. These disorders have conventionally been defined as renal osteodystrophy and classified based on bone biopsy, but due to a lack of bone biopsy data and validated radiological methods to evaluate bone morphology in children, it has been challenging to effectively assess renal osteodystrophy in pediatric CKD; the consequence has been the suboptimal management of bone disorders in children. CKD-mineral and bone disorder (CKD-MBD) is a new expression used to describe a systemic disorder of mineral and bone metabolism as a result of CKD. CKD-MBD is a triad of biochemical imbalances in calcium, phosphate, parathyroid hormone, and vitamin D; bone deformities and soft tissue calcification. This literature review aims to explore the pathogenesis, diagnostic approach, and treatment of CKD-MBD in children and the effects of renal osteodystrophy on growing skeleton, with a specific focus on the biological basis of this peculiar condition.

2.
BMC Nephrol ; 23(1): 336, 2022 10 20.
Article in English | MEDLINE | ID: mdl-36266621

ABSTRACT

BACKGROUND: Anaemia and iron deficiency (ID) are common in chronic kidney disease (CKD) patients and related to outcomes. There is growing interest about the role of iron supplementation in CKD, particularly ferric carboxymaltose (FCM), also in relation to the use of erythropoiesis stimulating agents (ESAs). Despite a greater knowledge on ID management in patients receiving haemodialysis, a paucity of data exists about peritoneal dialysis (PD). Furthermore, the aim of this paper is to provide the results of a nationwide Italian survey about ID in PD using the Delphi method. METHODS: A list of 16 statements (48 items) was developed about four main topics: (1) approach to iron therapy in PD; (2) management experience about iron therapy in PD; (3) ESA and iron in PD; (4) pharmacoeconomic impact. Using the Delphi methodology, the survey was distributed online to 36 Italian nephrologists with expertise in PD, who rated their level of agreement with each item on a 5-point Likert scale. Consensus was predefined as more than 66% of the panel agreeing/disagreeing with any given statement. RESULTS: Twenty-five experts (70%) answered the survey. 35 items (73%) achieved a consensus (8 negative and 27 positive). In particular, the diagnosis of ID is widely known, but some doubts exist about how frequently test it. The use of I.V. iron seems to be routinary and can save money reducing the administration of ESAs. However, internal protocols are welcome. CONCLUSIONS: Expert PD nephrologists know well the problem of ID and feel the necessity of shared protocols to optimize the iron therapy and consequently the use of ESAs.


Subject(s)
Anemia, Iron-Deficiency , Hematinics , Iron Deficiencies , Peritoneal Dialysis , Renal Insufficiency, Chronic , Humans , Delphi Technique , Consensus , Hemoglobins , Iron/therapeutic use , Ferric Compounds , Renal Insufficiency, Chronic/therapy , Renal Insufficiency, Chronic/chemically induced , Peritoneal Dialysis/adverse effects , Anemia, Iron-Deficiency/diagnosis , Anemia, Iron-Deficiency/drug therapy , Anemia, Iron-Deficiency/epidemiology
4.
G Ital Nefrol ; 37(1)2020 Feb 12.
Article in Italian | MEDLINE | ID: mdl-32068362

ABSTRACT

In 2011, a first peritoneal dialysis audit was held in the Lazio region to analyze the problems hindering the spread of this method and to improve the quality of care through the sharing of best practices across Centers. A scientific board was therefore set up, representing all the Centers offering PD, in order to assess clinical effectiveness using KPIs (Key Performance Indicators) and to quantify the objectives to be achieved. The analysis made it possible to identify the main problems and take action, all the while monitoring progress through KPIs. A second audit was carried out in 2017 and the collected data was analyzed and compared with the findings of the previous study. Overall, data showed an increase in prevalence, although the incidence showed a slight decrease. Indicators on the change of dialysis treatment, the dropout from domiciliary treatment and the incidence of late referral appeared stable over time. A slight improvement was observed in clinical data on peritonitis and on the length of hospitalization. All participants in the audit declared that sharing and discussing clinical practices had been really useful. In addition, through the drafting of practical documents (guides for patients, guidance on informed consent, protocols of clinical follow-up), a number of tools have been provided to ensure a uniformly high level of care across the different regional Centers.


Subject(s)
Advisory Committees/organization & administration , Benchmarking , Medical Audit , Peritoneal Dialysis/statistics & numerical data , Quality Improvement/statistics & numerical data , Hemodialysis, Home/statistics & numerical data , Humans , Italy , Kidney Failure, Chronic/therapy , Length of Stay , Medical Audit/methods , Patient Dropouts/statistics & numerical data , Peritoneal Dialysis/adverse effects , Peritoneal Dialysis/standards , Peritoneal Dialysis, Continuous Ambulatory/statistics & numerical data , Peritonitis/epidemiology , Quality Improvement/standards , Referral and Consultation , Treatment Outcome
5.
Intern Emerg Med ; 15(2): 273-280, 2020 03.
Article in English | MEDLINE | ID: mdl-31388894

ABSTRACT

The aim of this observational retrospective cohort study was to analyze the association between hyperchloremia and serum chloride variation with in-hospital acute kidney injury (AKI) and mortality in a general, no-ICU hospitalized population. We performed a retrospective study on inpatient population admitted to Fondazione Policlinico Universitario A. Gemelli IRCCS between January 2010 and December 2014 with inclusion of adult patients with at least two values available for chloride, sodium and creatinine. Hyperchloremia was defined as serum chloride concentration ≥ 108 mmol/L (moderate hyperchloremia: chloremia between 108-110 mmol/L, severe hyperchloremia: chloremia > 110 mmol/L). According to the time of onset of the electrolyte disturbance, hyperchloremia was then classified as hospital acquired (HA) and community acquired (CA). In patients with HA-hyperchloremia, chloride variation (ΔCl) was calculated. In-hospital AKI was defined according to creatinine kinetics criteria occurring 48 h after hospital admission. Logistic regression analysis was used to evaluate the association between the exposures of interest and in-hospital AKI and mortality. A total of 24,912 hospital admissions met the inclusion criteria. Regression analyses showed that only severe HA-hyperchloremia was associated with increased risk of in-hospital AKI [odds ratio (OR) 2.60, 95% confidence interval (CI) 1.58, 4.30, p value < 0.001] and death (OR 3.89, 95% CI 2.11, 7.18, p value < 0.001). With increasing ΔCl, the OR of in-hospital AKI increased progressively (p value for trend = 0.005). In conclusion, severe hyperchloremia is an independent predictor for in-hospital AKI and mortality; HA-hyperchloremia is more detrimental for patient outcome; higher ΔCl from hospital admission is associated with increased risk of AKI.


Subject(s)
Acute Kidney Injury/complications , Chlorides/analysis , Acute Kidney Injury/blood , Acute Kidney Injury/physiopathology , Aged , Aged, 80 and over , Chlorides/blood , Cohort Studies , Female , Hospitalization/statistics & numerical data , Humans , Male , Middle Aged , Odds Ratio , Patients' Rooms/organization & administration , Patients' Rooms/statistics & numerical data , Regression Analysis , Retrospective Studies , Risk Factors , Water-Electrolyte Imbalance/blood , Water-Electrolyte Imbalance/etiology
6.
Kidney Blood Press Res ; 44(4): 604-614, 2019.
Article in English | MEDLINE | ID: mdl-31330509

ABSTRACT

BACKGROUND/AIMS: Aim of our study was to describe the association between natremia (Na) fluctuation and hospital mortality in a general population admitted to a tertiary medical center. METHODS: We performed a retrospective observational cohort study on the patient population admitted to the Fondazione Policlinico A. Gemelli IRCCS Hospital between January 2010 and December 2014 with inclusion of adult patients with at least 2 Na values available and with a normonatremic condition at hospital admission. Patients were categorized according to all Na values recorded during hospital stay in the following groups: normonatremia, hyponatremia, hypernatremia, and mixed dysnatremia. The difference between the highest or the lowest Na value reached during hospital stay and the Na value read at hospital admission was used to identify the maximum Na fluctuation. Cox proportional hazards models were used to estimate hazard ratios (HRs) for in-hospital death in the groups with dysnatremias and across quartiles of Na fluctuation. Covariates assessed were age, sex, highest and lowest Na level, Charlson/Deyo score, cardiovascular diseases, cerebrovascular diseases, dementia, congestive heart failure, severe kidney disease, estimated glomerular filtration rate, and number of Na measurements during hospital stay. RESULTS: 46,634 admissions matched inclusion criteria. Incident dysnatremia was independently associated with in-hospital mortality (hyponatremia: HR 3.11, 95% CI 2.53, 3.84, p < 0.001; hypernatremia: HR 5.12, 95% CI 3.94, 6.65, p < 0.001; mixed-dysnatremia: HR 4.94, 95% CI 3.08, 7.92, p < 0.001). We found a higher risk of in-hospital death by linear increase of quartile of Na fluctuation (p trend <0.001) irrespective of severity of dysnatremia (HR 2.34, 95% CI 1.55, 3.54, p < 0.001, for the highest quartile of Na fluctuation compared with the lowest). CONCLUSIONS: Incident dysnatremia is associated with higher hospital mortality. Fluctuation of Na during hospital stay is a prognostic marker for hospital death independent of dysnatremia severity.


Subject(s)
Hospital Mortality , Sodium/metabolism , Adult , Aged , Cohort Studies , Female , Hospitalization , Humans , Hypernatremia , Hyponatremia , Male , Middle Aged , Prognosis , Proportional Hazards Models
7.
G Ital Nefrol ; 35(6)2018 Dec.
Article in Italian | MEDLINE | ID: mdl-30550035

ABSTRACT

ADH is a hormone secreted by neurohypophysis that plays different roles based on the target organ. At the renal level, this peptide is capable of causing electrolyte-free water absorption, thus playing a key role in the hydro-electrolytic balance. There are pathologies and disorders that jeopardize this balance and, in this field, ADH receptor inhibitors such as Vaptans could play a key role. By inhibiting the activation pathway of vasopressin, they are potentially useful in euvolemic and hypervolemic hypotonic hyponatremia. However, clinical trials in heart failure have not given favourable results on clinical outcomes. Even in SIADH, despite their wide use, there is no agreement by experts on their use. Since vaptans inhibit the cAMP pathway in tubular cells, their use has been proposed to inhibit cystogenesis. A clinical trial has shown favourable effects on ADPKD progression. Because vaptans have been shown to be effective in models of renal cysts disorders other than ADPKD, their use has been proposed in diseases such as nephronophthisis and recessive autosomal polycystic disease. Other possible uses of vaptans could be in kidney transplantation and cardiorenal syndrome. Due to the activity of ADH in coagulation and haemostasis, ADH's activation pathway by Desmopressin Acetate could be a useful strategy to reduce the risk of bleeding in biopsies in patients with haemorrhagic risk.


Subject(s)
Antidiuretic Hormone Receptor Antagonists/therapeutic use , Kidney Diseases/drug therapy , Molecular Targeted Therapy , Neurophysins/agonists , Neurophysins/antagonists & inhibitors , Protein Precursors/agonists , Protein Precursors/antagonists & inhibitors , Receptors, Vasopressin/drug effects , Vasopressins/agonists , Vasopressins/antagonists & inhibitors , Water-Electrolyte Imbalance/drug therapy , Antidiuretic Hormone Receptor Antagonists/pharmacology , Cadaver , Cyclic AMP/physiology , Forecasting , Humans , Hyponatremia/drug therapy , Hyponatremia/physiopathology , Kidney Diseases/physiopathology , Kidney Diseases, Cystic/drug therapy , Kidney Transplantation , Kidney Tubules, Collecting/drug effects , Kidney Tubules, Collecting/physiology , Neurophysins/physiology , Polycystic Kidney, Autosomal Dominant/drug therapy , Polycystic Kidney, Autosomal Dominant/physiopathology , Protein Precursors/physiology , Receptors, Vasopressin/agonists , Second Messenger Systems/drug effects , Tissue Donors , Vasopressins/physiology
8.
G Ital Nefrol ; 35(6)2018 Dec.
Article in Italian | MEDLINE | ID: mdl-30550038

ABSTRACT

We describe the clinical case of a patient who developed mixed cryoglobulinemia syndrome after hemodialysis treatment with dialysate temperature lower than 36°C despite the negativization of the viral genome for HCV after eradication therapy.


Subject(s)
Cryoglobulinemia/etiology , Purpura/etiology , Renal Dialysis/adverse effects , Anemia/etiology , Anemia/therapy , Blood Transfusion , Female , Glomerulonephritis, IGA/complications , Hepatitis C, Chronic/complications , Humans , Kidney Failure, Chronic/etiology , Kidney Failure, Chronic/therapy , Kidney Transplantation , Middle Aged , Postoperative Complications , Thrombocytopenia/etiology
9.
G Ital Nefrol ; 35(4)2018 Jul.
Article in Italian | MEDLINE | ID: mdl-30035444

ABSTRACT

Enteric hyperoxaluria is one of the most frequent complications of bariatric surgery. In this setting the prevalence of kidney stones is increased. Currently the treatment of enteric hyperoxaluria is based not only on the reduction of urinary oxalate but even controlling other lithogenic risk factors, like urinary volume and urinary citrate levels. This case report suggests a possible benefit using magnesium citrate in addition to calcium supplementation, in the treatment of hyperoxaluria caused by enteric malabsorption.


Subject(s)
Kidney Calculi/etiology , Malabsorption Syndromes/complications , Adult , Female , Humans , Recurrence
10.
G Ital Nefrol ; 35(3)2018 May.
Article in Italian | MEDLINE | ID: mdl-29786188

ABSTRACT

Mutations of the CYP24A1 gene are associated with alterations in the activity of the enzyme 25-OH-D-24-hydroxylase, resulting in dysfunction of the metabolism of vitamin D. This enzymatic deficiency may cause hypercalcemia, low parathyroid hormone levels, hypercalciuria, nephrolithiasis and nephrocalcinosis. The clinical case of a young woman with recurrent renal lithiasis, hypercalcemia and hypercalciuria is described. These features are linked to deficiency of the enzyme 25-OH-D-24-hydroxylase, therefore to a biallelic mutation of the CYP24A1 gene.


Subject(s)
Hypercalcemia/genetics , Kidney Calculi/genetics , Vitamin D3 24-Hydroxylase/genetics , Adult , Calcium/blood , Calcium/urine , Cholecalciferol/blood , Citrates/urine , Female , Genotype , Humans , Hypercalcemia/complications , Hypercalciuria/etiology , Hypercalciuria/genetics , Kidney Calculi/blood , Kidney Calculi/etiology , Kidney Calculi/urine , Mutation, Missense , Parathyroid Hormone/blood , Phosphorus/blood , Recurrence , Sequence Deletion , Vitamin D/metabolism , Vitamin D3 24-Hydroxylase/deficiency
11.
Telemed J E Health ; 24(4): 315-323, 2018 04.
Article in English | MEDLINE | ID: mdl-29024613

ABSTRACT

BACKGROUND: For chronic kidney disease patients who progress to end-stage renal disease, survival is dependent on renal replacement therapy in the form of kidney transplantation or chronic dialysis. Peritoneal dialysis (PD), which can be performed at home, is both more convenient and less costly than hemodialysis that requires three 4-h visits per week to the dialysis facility and complicated equipment. Remote therapy management (RTM), technologies that collect medical information and transmit it to healthcare providers for patient management, has the potential to improve the outcomes of patients receiving automated peritoneal dialysis (APD) at home. OBJECTIVE: Estimate through a simulation study the potential impact of RTM on APD patients use of healthcare resources and costs in the United States, Germany, and Italy. METHODS: Twelve APD patient profiles were developed to reflect potential clinical scenarios of APD therapy. Two versions of each profile were created to simulate healthcare resource use, one assuming use of RTM and one with no RTM. Eleven APD teams (one nephrologist, one nurse) estimated resources that would be used. RESULTS: Results from U.S., German, and Italian clinicians found that RTM could avoid use of 59, 49, and 16 resources over the 12 profiles, respectively. Estimated reduced utilization across the three countries ranged from one to two hospitalizations, one to four home visits, two to five emergency room visits, and four to eight unplanned clinic visits. Total savings across all scenarios were $23,364 in the United States, $11,477 in Germany, and $7,088 in Italy. CONCLUSION: In a simulated environment, early intervention enabled by RTM reduced healthcare resource utilization and associated costs.


Subject(s)
Home Care Services/organization & administration , Kidney Failure, Chronic/therapy , Monitoring, Ambulatory/methods , Peritoneal Dialysis/methods , Telemedicine/methods , Computer Simulation , Female , Health Expenditures/statistics & numerical data , Home Care Services/economics , Humans , Male , Monitoring, Ambulatory/economics , Patient Care Team/organization & administration , Telemedicine/economics , Young Adult
12.
G Ital Nefrol ; 28(3): 305-13, 2011.
Article in Italian | MEDLINE | ID: mdl-21626499

ABSTRACT

Hyponatremia is one of the most frequent ion and water disorders. It is generally due to disproportionate renal water retention. Severe hyponatremia (<125 mEq/L) is associated with well-known clinical symptoms and manifestations. However, even mild reductions in sodium blood levels have been shown to be associated with increased mortality and with the risk of falls and fractures. The diagnosis of hyponatremia, although requiring simple clinical and laboratory tests, may be complex and difficult. Treatment should be tailored to the clinical manifestations and severity of hyponatremia. Vaptans may be used in euvolemic or hypervolemic hyponatremia and particularly in SIADH.


Subject(s)
Hyponatremia/diagnosis , Hyponatremia/therapy , Humans , Hyponatremia/etiology , Hyponatremia/physiopathology , Practice Guidelines as Topic
SELECTION OF CITATIONS
SEARCH DETAIL
...